AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio

 
• By Alaric DeArment
  
businessman and businesswoman are exchanging document or contract
AC Immune is acquiring AFFiRiS's alpha-synuclein portfolio for $63.7m in cash and stock • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business